Potential disease-modifying pharmacotherapies for Parkinson's Disease outcomes

11 July 2024

Real-world effectiveness of potential disease-modifying pharmacotherapies for treatment and prevention of Parkinson’s Disease

Professor Li Wei and her team have been recently awarded a research grant from Cure Parkinson’s Trust to study potential disease-modifying pharmacotherapies for treatment and prevention of Parkinson’s using observational data with a target trial approach framework.

The researchers will examine the effects of istradefylline, montelukast, and ursodeoxycholic acid on progression or prevention of Parkinson’s/early-stage Parkinson’s. The research results will guide and de-risk disease modifying clinical trials that will be conducted within 2-3 years within the EJS ACT-PD platform (http://ejsactpd.com/).

Professor Li Wei profile